Sanofi
Pharmaceutical & Health Products · Lobbying Client
Sanofi's Federal Lobbying Record
At $11.6M in disclosed federal lobbying, Sanofi ranks as a major spender — well above the typical filer. Outlays in this range generally reflect a sustained presence in Washington, with at least one full-time government affairs lead and a stable of outside lobbyists engaged on the organization's priority issues.
Across the 5-year window from 2020 to 2024, Sanofi's annual disclosed lobbying spend has held roughly steady — $2.5M at the start versus $2.3M at the most recent year-end. Year-to-year wobbles inside that range usually reflect timing of legislative cycles rather than a strategic shift.
Sanofi's disclosed lobbying focuses on a narrow 4-issue footprint. A focused issue list usually means the organization concentrates its federal engagement on a small set of bills or rulemakings directly relevant to its core business.
2 of 8 lobbyists reported by Sanofi (25%) disclose prior federal government service. That share is common at established government affairs operations that explicitly hire from agency and committee staff.
Among the named bench, lobbyists with disclosed prior federal service include James E. Sharp (Former Assistant Secretary of the Treasury); Wayne E. Berman (Former Deputy Assistant Secretary of Defense). The covered-position field on LDA cover sheets captures executive-branch and senior congressional roles held within the prior two years.
Within the Pharmaceutical & Health Products sector, Sanofi ranks #15 of 34 tracked organizations by disclosed lobbying spend. The sector leader is Pharmaceutical Research & Manufacturers of America at $135.8M; the sector average is $16.7M. Sanofi's $11.6M sits 30% below the sector average.
Sanofi's LobbySpend Influence Score of 52/100 (grade C) is the most common grade in the index — it covers organizations with established but moderate federal advocacy programs. The score combines disclosed total spend (40%), issue breadth (30%), and revolving-door connections (30%). A C-grade is typical of mid-size corporations and trade associations with steady quarterly filings on a focused issue set.
Every figure above is sourced from Senate lobbying disclosure filings submitted under the Lobbying Disclosure Act of 1995. Per-issue dollar splits and covered-position flags are filer-reported and may be amended after initial submission.
Track Sanofi's lobbying filings
Subscribe for LobbySpend updates by email. No spam, unsubscribe anytime.
Annual Lobbying Spend
Policy Issues
Government Entities Contacted
Recent Filings
| Period | Registrant | Issues | Lobbyists | Amount |
|---|---|---|---|---|
| 2024 Oct-Dec | Akin Gump Strauss Hauer & Feld | PHAMEDHCR | 1 | $522K |
| 2024 Jul-Sep | Cornerstone Government Affairs | PHAHCRMED | 1 | $662K |
| 2024 Apr-Jun | Invariant LLC | MEDPHAHCR | 1 | $523K |
| 2024 Jan-Mar | Mehlman Consulting | PHAGOVHCR | 4 | $539K |
| 2023 Oct-Dec | Jones Day | HCRMEDGOV | 3 | $553K |
| 2023 Jul-Sep | Peck Madigan Jones | PHAMED | 4 | $474K |
| 2023 Apr-Jun | Covington & Burling | GOVHCR | 1 | $634K |
| 2023 Jan-Mar | Invariant LLC | MEDHCRGOV | 4 | $475K |
Sanofi Lobbying FAQ
Sanofi has spent $11.6M on federal lobbying across 4 policy areas. This includes spending on registered lobbyists and direct government contacts.
Sanofi lobbies on 4 policy issues, including Health Issues, Pharmacy, Medical/Disease Research, Government Issues. These disclosures are filed quarterly with the Senate Office of Public Records.
Sanofi has an Influence Score of 52/100 (Grade C). This proprietary score is based on total lobby spend (40%), policy issue breadth (30%), and revolving door connections (30%).
Sanofi employs 8 registered lobbyists, of whom 2 have revolving door connections, meaning they previously held government positions before becoming lobbyists.
Sanofi has contacted 5 government entities as part of their lobbying activities, including Federal Communications Commission, Small Business Administration, Securities & Exchange Commission.
Explore Other Lobbying Organizations
$387.8M lobbying spend · Trade Association · Influence Score B
$348.2M lobbying spend · Real Estate · Influence Score B
$135.8M lobbying spend · Pharmaceutical & Health Products · Influence Score B
$128.0M lobbying spend · Healthcare · Influence Score B
Lobbying data is sourced from quarterly Lobbying Disclosure Act (LDA) filings with the Senate Office of Public Records. Influence Scores combine total spend (40%), issue breadth (30%), and revolving door connections (30%). Filings may be amended after initial submission.